Minerva Neurosciences, Inc

Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia

17 May 2018 08:01:03 By Nasdaq GlobeNewswire

Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates

03 May 2018 07:30:13 By Nasdaq GlobeNewswire

Minerva Neurosciences to Report First Quarter 2018 Financial Results and Business Updates on May 3, 2018

26 Apr 2018 08:30:48 By Nasdaq GlobeNewswire

Minerva Neurosciences Screens First Patient in Phase 2b Trial of MIN-117 to Treat Major Depressive Disorder

09 Apr 2018 08:30:41 By Nasdaq GlobeNewswire

Minerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday, March 22

15 Mar 2018 08:30:48 By Nasdaq GlobeNewswire

Minerva Neurosciences Reports Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates

12 Mar 2018 07:30:21 By Nasdaq GlobeNewswire

Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018

05 Mar 2018 08:30:27 By Nasdaq GlobeNewswire

Minerva Neurosciences Names Remy Luthringer as Executive Chairman and William Doyle as Lead Independent Director

05 Feb 2018 08:30:33 By Nasdaq GlobeNewswire

Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial Comparing Seltorexant (MIN-202) Versus Quetiapine as Adjunctive Therapy to Antidepressants in Patients With Major Depressive Disorder

21 Dec 2017 08:00:49 By Nasdaq GlobeNewswire

Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia

19 Dec 2017 08:00:59 By Nasdaq GlobeNewswire

Minerva Neurosciences Names Richard Russell President

11 Dec 2017 16:30:17 By Nasdaq GlobeNewswire

Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors

11 Dec 2017 08:15:10 By Nasdaq GlobeNewswire

Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia Disorder

06 Dec 2017 08:30:22 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: Minerva Neurosciences, Inc

14 Nov 2017 09:46:22 By NetDania Notify

NetDania - New 12 months Low: Minerva Neurosciences, Inc

09 Nov 2017 09:45:01 By NetDania Notify

NetDania - New 12 months Low: Minerva Neurosciences, Inc

08 Nov 2017 10:47:24 By NetDania Notify

Minerva Neurosciences to Present at Jefferies 2017 London Healthcare Conference on November 15, 2017

08 Nov 2017 09:00:50 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: Minerva Neurosciences, Inc

07 Nov 2017 10:10:16 By NetDania Notify

Minerva Neurosciences Reports Third Quarter 2017 Financial Results and Business Updates

06 Nov 2017 07:30:29 By Nasdaq GlobeNewswire

Minerva Neurosciences Names Dr. Justine Lalonde as Senior Vice President, Product Strategy

31 Oct 2017 08:00:43 By Nasdaq GlobeNewswire